Trial Profile
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Aug 2007 Status change from recruiting to in progress.
- 18 Aug 2005 New trial record.